Pharmaceuticals Europe

Europe RSV Vaccines Market Analysis, 2024–2034

Updated Reviewed by Chandani Patel

Europe RSV Vaccines Market Industry Trends and Forecast to 2034: Segmented by (Product, Age, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

Europe · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $679.7 Mn Placeholder estimate
Estimate 2025 $754.4 Mn 17.2% of the global market
Projected 2034 $1.93 Bn 155.8% Adds $1.18 Bn over 9 forecast years
CAGR 2025–2034 11.0% Faster than 68% of 180 Pharmaceuticals markets here
Key players 5
  • Europe is 17.18% of the global market.
  • Among regions, the largest is North America at $1.91 Bn.
  • Fastest growing: Africa at 13.9% a year.
  • Europe ranks 3rd of 6 by size among regions.

Market size projection

Europe

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$1.18 Bn total, 2026–2034

Year-by-year market size, 2024–2034
RSV Vaccines Market market size by year, Europe
YearMarket sizeChange that yearSince 2025
2024 (estimate) $679.7 Mn — —
2025 (base) $754.4 Mn +$74.8 Mn —
2026 (forecast) $837.4 Mn +$83.0 Mn +11%
2027 (forecast) $929.5 Mn +$92.1 Mn +23.2%
2028 (forecast) $1.03 Bn +$102.2 Mn +36.8%
2029 (forecast) $1.15 Bn +$113.5 Mn +51.8%
2030 (forecast) $1.27 Bn +$126.0 Mn +68.5%
2031 (forecast) $1.41 Bn +$139.8 Mn +87%
2032 (forecast) $1.57 Bn +$155.2 Mn +107.6%
2033 (forecast) $1.74 Bn +$172.3 Mn +130.5%
2034 (forecast) $1.93 Bn +$191.2 Mn +155.8%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

Europe RSV Vaccines Market Analysis at a glance
Market size, 2025$754.4 Mn placeholder estimate
Forecast, 2034$1.93 Bn placeholder estimate
Growth (CAGR), 2025–203411.0% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsProduct, age and end user (see all)
Key playersGSK PLC, Pfizer Inc., Moderna, Sanofi, AstraZeneca (see all)
Regulator in EuropeEMASource: European Medicines Agency. Checked 14 Nov 2026.
Active clinical trials11 in EuropeSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Europe. Retrieved 12 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The Europe RSV Vaccines Market Analysis Executive Summary

RSV vaccines protect older adults, pregnant women (for their babies) and infants against respiratory syncytial virus, a common cause of serious chest infections.

Key segments of the RSV Vaccines market include product (Older Adult Vaccines, Maternal Vaccines and Infant Monoclonal Antibodies) and age (Infants, Older Adults and Pregnant Women).

Bar chart: Europe RSV Vaccines market size, 2024–2034, placeholder estimates. $679.7 Mn in 2024, $754.4 Mn in 2025 and $1.93 Bn in 2034, 11.0% CAGR.
Europe RSV Vaccines market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

Europe RSV Vaccines Market Dynamics

Market Growth Drivers

Rising antimicrobial resistance, outbreaks of new and returning diseases, climate change spreading infections and strong global funding for prevention are driving the RSV Vaccines market.

Opportunity

New vaccines, rapid tests and public-private funding for neglected diseases give the RSV Vaccines market room to grow, especially in Asia, Africa and Latin America.

Market Restraints

Low prices in poorer markets, weak returns for new antibiotics, vaccine hesitancy and cold-chain problems hold back the RSV Vaccines market.

Competitive Landscape for RSV Vaccines Market in Europe

The RSV Vaccines market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for RSV Vaccines Market in Europe

RSV Vaccines in Europe: rules, payment and research

In the EU, many new medicines are authorised once for every member state by the European Commission, after review by the European Medicines Agency (EMA).⁠[1] In the countries we cover here, medicines are approved by ANSM (France)⁠[2], BfArM (Germany)⁠[3], AIFA (Italy)⁠[4], Ministry of Health (Russia)⁠[5], AEMPS (Spain)⁠[6] and MHRA (UK)⁠[7]. Each country runs its own health system and decides prices and reimbursement; since January 2025, EU countries also share joint clinical assessments of some new medicines.⁠[8] ClinicalTrials.gov lists 11 studies on RSV Vaccines that are recruiting, active or about to start in Europe.⁠[9]

[1] European Medicines Agency. Checked 14 Nov 2026.

[2] ANSM, French medicines agency. Checked 14 Nov 2026.

[3] Federal Institute for Drugs and Medical Devices (BfArM). Checked 14 Nov 2026.

[4] Italian Medicines Agency (AIFA). Checked 14 Nov 2026.

[5] Ministry of Health of the Russian Federation. Checked 14 Nov 2026.

[6] Spanish Agency of Medicines and Medical Devices (AEMPS). Checked 14 Nov 2026.

[7] Medicines and Healthcare products Regulatory Agency. Checked 14 Nov 2026.

[8] European Commission, health technology assessment. Checked 14 Nov 2026.

[9] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Europe. Retrieved 12 Nov 2026.

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for RSV Vaccines. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Europe.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in RSV Vaccines right now, from free public sources.

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

RSV Vaccines in context

Free data on this topic

Quick answers

Frequently asked questions

How big is the RSV Vaccines market in Europe?
Placeholder estimate: about $754.4 Mn in 2025, rising to about $1.93 Bn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the RSV Vaccines market in Europe growing?
Placeholder estimate: about 11.0% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the RSV Vaccines market report cover?
The report splits the market by product (Older Adult Vaccines, Maternal Vaccines, Infant Monoclonal Antibodies), age (Infants, Older Adults, Pregnant Women) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the RSV Vaccines market?
Key players include GSK PLC, Pfizer Inc., Moderna, Sanofi and AstraZeneca.
What is driving the RSV Vaccines market?
Rising antimicrobial resistance, outbreaks of new and returning diseases, climate change spreading infections and strong global funding for prevention are driving the RSV Vaccines market.
Who regulates RSV Vaccines in Europe?
In the EU, many new medicines are authorised once for every member state by the European Commission, after review by the European Medicines Agency (EMA). Source: European Medicines Agency. Checked 14 Nov 2026.
How is healthcare paid for in Europe?
Each country runs its own health system and decides prices and reimbursement; since January 2025, EU countries also share joint clinical assessments of some new medicines. Source: European Commission, health technology assessment. Checked 14 Nov 2026.
How many clinical trials on RSV Vaccines are running in Europe?
11 studies are recruiting, active or about to start in Europe, counted across the 6 countries we report on there, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Europe. Retrieved 12 Nov 2026.
How much research is published on RSV Vaccines?
PubMed lists 397 papers on RSV Vaccines added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Back to Catalogue

Related Pharmaceuticals reports in Europe

See all

Related on vaccines and respiratory

See the topic